<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829827</url>
  </required_header>
  <id_info>
    <org_study_id>EP0078</org_study_id>
    <secondary_id>2016-002107-26</secondary_id>
    <nct_id>NCT02829827</nct_id>
  </id_info>
  <brief_title>A Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)</brief_title>
  <official_title>An Open-label Adaptive Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Radiprodil in Subjects With Drug-resistant Infantile Spasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and
      the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant
      infantile spasms
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">March 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from the first day of radiprodil at maintenance dose</time_frame>
    <description>Clinical response is defined as no spasms on Day 14 of treatment with the maintenance dose of radiprodil. This is the primary efficacy variable for Part A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with electro-clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from the first day of radiprodil at maintenance dose</time_frame>
    <description>Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is the primary efficacy variable for Part B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with electro-clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from the first day of radiprodil at maintenance dose</time_frame>
    <description>Electro-clinical response is defined as no spasms and resolution of hypsarrythmia on Day 14 of treatment with the maintenance dose of radiprodil. This is the secondary efficacy variable for Part A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinical response on day 14 of treatment with the maintenance dose of radiprodil</measure>
    <time_frame>Day 14, counting from Day 14 of treatment with the maintenance dose of radiprodil</time_frame>
    <description>Clinical response is defined as no spasms on Day 14 of treatment with the maintenance dose of radiprodil. This is the secondary efficacy variable for Part B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of spasms</measure>
    <time_frame>During the first 14 days of treatment with radiprodil</time_frame>
    <description>Time to cessation of spasms for clinical responders on Day 14 of treatment with the maintenance dose of radiprodol. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders with clinical relapse</measure>
    <time_frame>12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil</time_frame>
    <description>The percentage of clinical responders on Day 14 of treatment with the maintenance dose of radiprodil with clinical relapse within 12 months. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical relapse from the day of spasm cessation</measure>
    <time_frame>From day of spasms cessation up to 42 months of age</time_frame>
    <description>This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of electro-clinical responders with electro-clinical relapse</measure>
    <time_frame>12 months, counting from Day 14 of treatment with the maintenance dose of radiprodil</time_frame>
    <description>The percentage of electro-clinical responders on Day 14 of treatment with the maintenance dose of radiprodil with electro-clinical relapse within 12 months. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to electro-clinical relapse from the day of spasm cessation</measure>
    <time_frame>From day of spasms cessation up to 42 months of age</time_frame>
    <description>This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with extended clinical response</measure>
    <time_frame>28 days, counting from Day 14 (inclusive) of treatment with the maintenance dose of radiprodil</time_frame>
    <description>Extended clinical response is defined as no spasms for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with extended electro-clinical response</measure>
    <time_frame>28 days, counting from Day 14 (inclusive) of treatment with the maintenance dose of radiprodil</time_frame>
    <description>Extended electro-clinical response is defined as no spasms and resolution of hypsarrythmia for 28 consecutive days from Day 14 of treatment with the maintenance dose of radiprodil. This is a secondary efficacy variable for parts A and B.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infantile Spasms (IS)</condition>
  <arm_group>
    <arm_group_label>Radiprodil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will enter an individualized dose titration schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiprodil</intervention_name>
    <description>Radiprodil at individualized doses.</description>
    <arm_group_label>Radiprodil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female between 2 and 14 months of age

          -  The diagnosis of infantile spasms (IS)

          -  Subject has drug-resistant IS

        Exclusion Criteria:

          -  More than 6 months have passed since the diagnosis of Infantile Spasms (IS)

          -  Current treatment with cannabinoids

          -  Subject has hematocrit greater than 60

          -  Subject has any medical condition that, in the opinion of the Investigator, could
             jeopardize or would compromise the subject's ability to participate in this study

          -  Subject has a history or current condition predisposing to respiratory dysfunction

          -  Current treatment with felbamate

          -  Current treatment with perampanel

          -  Ketogenic diet

          -  Clinically significant lab abnormalities

          -  Clinically significant abnormality on ECG that, in the opinion of the Investigator,
             increases the safety risks of participating in the study

          -  Subject has a lethal or potentially lethal condition other than IS, with a significant
             risk of death before 18 months of age such as non-ketotic hyperglycinemia

          -  Body weight is below 4 kg

          -  Known history of severe anaphylactic reaction secondary to medication intake or
             serious blood dyscrasias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>14 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1844599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ep0078 202</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0078 201</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0078 501</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0078 401</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0078 302</name>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0078 102</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0078 101</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiprodil</keyword>
  <keyword>Infantile spasms</keyword>
  <keyword>IS</keyword>
  <keyword>Infantile</keyword>
  <keyword>Spasms</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>Drug-resistant</keyword>
  <keyword>West Syndrome</keyword>
  <keyword>Hypsarrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

